Oppenheimer analyst Mark Breidenbach downgrades Forma Therapeutics Hldgs (NASDAQ:FMTX) from Outperform to Perform.
Oppenheimer Downgrades Forma Therapeutics Hldgs to Perform
Oppenheimer analyst Mark Breidenbach downgrades Forma Therapeutics Hldgs (NASDAQ:FMTX) from Outperform to Perform.
Related Posts
Deutsche Bank Upgrades Accor to Buy
Deutsche Bank analyst Andre Juillard upgrades Accor (OTC:ACCYY) from Hold to Buy.
Compass Q4 EPS $(0.43) Misses $(0.31) Estimate, Sales $1.61B Inline
Compass (NYSE:COMP) reported quarterly losses of $(0.43) per share which missed the analyst consensus estimate of $(0.31) by 38.71 percent. The company reported quarterly sales of $1.61 billion which met the analyst